HomeComparePNNT vs LLY

PNNT vs LLY: Dividend Comparison 2026

PNNT yields 21.82% · LLY yields 0.70%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PNNT wins by $2485.58M in total portfolio value
10 years
PNNT
PNNT
● Live price
21.82%
Share price
$4.40
Annual div
$0.96
5Y div CAGR
57.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2487.12M
Annual income
$2,270,557,040.91
Full PNNT calculator →
LLY
LLY
● Live price
0.70%
Share price
$886.67
Annual div
$6.23
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.54M
Annual income
$1,207,534.19
Full LLY calculator →

Portfolio growth — PNNT vs LLY

📍 PNNT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPNNTLLY
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PNNT + LLY cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PNNT pays
LLY pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PNNT
Annual income on $10K today (after 15% tax)
$1,854.55/yr
After 10yr DRIP, annual income (after tax)
$1,929,973,484.77/yr
LLY
Annual income on $10K today (after 15% tax)
$59.72/yr
After 10yr DRIP, annual income (after tax)
$1,026,404.06/yr
At 15% tax rate, PNNT beats the other by $1,928,947,080.71/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PNNT + LLY for your $10,000?

PNNT: 50%LLY: 50%
100% LLY50/50100% PNNT
Portfolio after 10yr
$1244.33M
Annual income
$1,135,882,287.55/yr
Blended yield
91.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on LLY right now

PNNT
Analyst Ratings
3
Buy
11
Hold
1
Sell
Consensus: Hold
Price Target
$6.17
+40.2% upside vs current
Range: $5.50 — $7.00
Altman Z
-0.1
Piotroski
6/9
LLY
Analyst Ratings
33
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$1,243.95
+40.3% upside vs current
Range: $985.00 — $1,350.00
Altman Z
7.7
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PNNT buys
0
LLY buys
0
No recent congressional trades found for PNNT or LLY in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPNNTLLY
Forward yield21.82%0.70%
Annual dividend / share$0.96$6.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR57.6%100%
Portfolio after 10y$2487.12M$1.54M
Annual income after 10y$2,270,557,040.91$1,207,534.19
Total dividends collected$2470.97M$1.49M
Payment frequencyquarterlyquarterly
SectorBDCHealthcare
Analyst consensusHoldBuy
Analyst price target$6.17$1,243.95

Year-by-year: PNNT vs LLY ($10,000, DRIP)

YearPNNT PortfolioPNNT Income/yrLLY PortfolioLLY Income/yrGap
1← crossover$14,139$3,438.55$10,841$140.53+$3.3KPNNT
2$22,289$7,160.64$11,884$284.74+$10.4KPNNT
3$40,476$16,626.77$13,299$583.47+$27.2KPNNT
4$87,781$44,472.18$15,451$1,220.47+$72.3KPNNT
5$235,984$142,058.38$19,183$2,650.30+$216.8KPNNT
6$815,001$562,497.15$26,676$6,150.32+$788.3KPNNT
7$3,733,376$2,861,325.49$44,530$15,986.45+$3.69MPNNT
8$23,300,323$19,305,611.09$97,527$49,880.25+$23.20MPNNT
9$202,397,772$177,466,426.06$308,551$204,197.51+$202.09MPNNT
10$2,487,122,657$2,270,557,040.91$1,537,684$1,207,534.19+$2485.58MPNNT

PNNT vs LLY: Complete Analysis 2026

PNNTBDC

PennantPark Investment Corporation, a business development company is a private equity fund specializes in direct and mezzanine investments in middle market companies. It invests in the form of mezzanine debt, senior secured loans, and equity investments. The fund typically invests in buildings and real estate, hotels, gaming and leisure, technology, telecommunications, transportation, information technology services, electronics, healthcare & pharmaceuticals, education and childcare, financial services, printing and publishing, consumer products, business services, energy & Related Services and utilities, distribution, oil and gas, media, environmental services, aerospace and defense, building materials, capital equipment, chemicals, plastics, & rubber, food & beverage, wholesale, manufacturing and basic industries and retail. It invests in equity securities and debt transactions through preferred stock, common stock, warrants, options, senior secured debt, subordinated debt, subordinated loans, first lien debt, mezzanine loans, and distressed debt securities and private equity co-investments. It seeks to invest in companies based in the United States. The fund seeks to invest between $10 million and $100 million cross the capital structure (senior secured loans, subordinated debt, and other investments) in its portfolio companies with EBITDA between $10 to $50 million. Its mezzanine loans, senior secured loans, and other investments in its portfolio companies are between $15 million and $50 million. The fund may also make non-control equity and debt investments.

Full PNNT Calculator →

LLYHealthcare

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Full LLY Calculator →
📬

Get this PNNT vs LLY comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PNNT vs SCHDPNNT vs JEPIPNNT vs OPNNT vs KOPNNT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.